CSL has announced plans to expand its US presence over the next five years (as reported on November 18, 2025) resulting in approximately $1.5 billion in US capital investments. These investments will focus on CSL’s US manufacturing capabilities of plasma-derived therapies. These planned investments are subject to approval by CSL’s Board of Directors. 

Since 2018, CSL has invested over $3 billion into its US operations to bring its total US headcount to nearly 19,000, representing about 65% of CSL’s workforce. 

The news to increase capital investments in the US comes amid a restructuring plan previously announced by the company. In August (August 2025), the company reported that on a global basis, it was taking a series of initiatives that will result in a net headcount reduction of up to 15% of its employee base and which includes changes to its R&D structure, operating model, and plasma network. In its plasma network, in August 2025, the company reported that it had closed 22 underperforming centers, representing 7% of CSL Plasma’s US footprint. The company also announced plans to demerge CSL Seqirus, a provider of seasonal influenza vaccines, before the end of Financial Year 2026. 

Source: CSL